----item----
version: 1
id: {5F391F88-01A0-41E1-AC7E-5BEEC39532A4}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/06/17/Clementia raises $60m after $10m Series A boost
parent: {8B19334F-ECBE-485B-8DBC-E15AECF32AEF}
name: Clementia raises $60m after $10m Series A boost
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 6afbdc8d-725c-45c3-bd18-7b1531c04905

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{29C8E5B9-B01E-4DEE-A123-14D70756095B}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 50

 Clementia raises $60m after $10m Series A boost  
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 47

Clementia raises $60m after $10m Series A boost
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 985

<p> Clementia Pharmaceuticals raised $60m in mezzanine financing for the ongoing development of its sole drug candidate palovarotene about six months after the Canadian company closed a $10m extension of its first venture capital round, which brought the Series A total to $32.5m. New Enterprise Associates led the mezzanine deal with participation from the pharma company UCB, three other new investors and two prior backers, including OrbiMed Advisors. </p> <p> Montreal, Quebec-based Clementia is running a Phase II clinical trial and has been granted orphan drug designations in the US and EU as well as fast track status in the US for its retinoic acid receptor gamma agonist as a treatment for fibrodysplasia ossificans progressive (FOP), a genetic disease characterized by tissue swelling and abnormal bone formation. Palovarotene was licensed from Roche, which discontinued development following Phase II studies in chronic obstructive pulmonary disease (COPD). </p> <p><p><p> 
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 459

<p> Clementia Pharmaceuticals raised $60m in mezzanine financing for the ongoing development of its sole drug candidate palovarotene about six months after the Canadian company closed a $10m extension of its first venture capital round, which brought the Series A total to $32.5m. New Enterprise Associates led the mezzanine deal with participation from the pharma company UCB, three other new investors and two prior backers, including OrbiMed Advisors. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 47

Clementia raises $60m after $10m Series A boost
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150617T180001
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150617T180001
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150617T180001
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029063
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 50

 Clementia raises $60m after $10m Series A boost  
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{B322F30F-1522-4633-91A4-A2EF3216848C}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 11

Expert View
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359000
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042412Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

6afbdc8d-725c-45c3-bd18-7b1531c04905
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042412Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
